Tyrosinemia Type I in Japan: A Report of Five Cases

  • Kimitoshi Nakamura
  • Michinori Ito
  • Yosuke Shigematsu
  • Fumio Endo
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 959)

Abstract

Tyrosinemia type I in Japan was reported for the first time in 1957 by Sakai et al. (Jikei Med J 2:1–10, 1957) and Kitagawa et al. (Proc Jpn Acad Ser B 88:192–200, 1957). Five cases of patients with tyrosinemia type I were reported to be definitively diagnosed in Japan. The first case was reported by Sakai et al. and Kitagawa et al. To the best of our knowledge, this was the first definite report in the world. The second and third cases were those of a brother and a sister who underwent liver transplantation and who were the children of a Japanese-descent migrant worker; the fourth case was that of a girl who underwent liver transplantation after 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) treatment, which was reported by Hata et al.; and the fifth case was that of a patient who was administered NTBC, which was reported by Ito et al. These were of the subacute type, wherein residual activity was considerably present. When combined therapy with a low phenylalanine and tyrosine diet and NTBC administration is started after early diagnosis, patients can survive without liver transplantation. Development of liver cancer is not found in the cases in Japan, but performing liver transplantation without delay is necessary when liver cancer is found.

Keywords

HT1 Japan NTBC 

Abbreviations

AFP

alpha-fœtoprotein

ALP

alkaline phosphatase

APPT

activated partial thromboplastin time

FAH

fumarylacetoacetate hydrolase

HPT

heptoplastin T

γ-GTP

γ-glutamyl transferase

References

  1. Grompe M et al (1995) Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinemia type 1. Nat Genet 10:453–460CrossRefPubMedGoogle Scholar
  2. Hata I, Shigematsu Y (2012) A case of hypertyrosinemia I. Annual report of the Grant-in-aid for the research on rare and intractable diseases, Health and Labour Sciences Research. (Japanese)Google Scholar
  3. Ito M, Matsuda J, Shinahara H (2005) A case of hypertyrosinemia I with favorable prognosis after administration of long-term NTBC. Bull Spec Formula 41:27–30. (Japanese)Google Scholar
  4. Kelsey G et al (1993) Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1. Genes Dev 7:2285–2297CrossRefPubMedGoogle Scholar
  5. Lindstedt S et al (1992) Treatment of hereditary tyrosinemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813–817CrossRefPubMedGoogle Scholar
  6. Michell GA et al (2001) Hypertyrosinemia. In: Scriver CR et al (eds) The metabolic and molecular bases of inherited diseases, 8th edn. McGraw Hill, New York, pp 1777–1805Google Scholar
  7. Nakamura K, Matsumoto S, Mitsubuchi H et al (2015) Diagnosis and treatment of hereditary tyrosinemia in Japan. Pediatr Int 57:37–40CrossRefPubMedGoogle Scholar
  8. Sakai K, Kitagawa T (1957) An atypical case of tyrosinosis. Part 1. Jikei Med J 2:1–10CrossRefGoogle Scholar
  9. Shigematsu K, Hata I (2007) Annual report for the research on rare and intractable diseases. Health Labour Sci Res Grants:86–88Google Scholar
  10. Ueda A, Ito T, Okubo Y et al (2005) A case of hypertyrosinemia I. Bull Spec Formula 41:23–26Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Kimitoshi Nakamura
    • 1
  • Michinori Ito
    • 2
  • Yosuke Shigematsu
    • 3
  • Fumio Endo
    • 1
  1. 1.Department of Pediatrics, Graduate School of Medical SciencesKumamoto UniversityKumamotoJapan
  2. 2.Kagawa Children’s National HospitalKagawaJapan
  3. 3.Department of Health ScienceFukui UniversityFukuiJapan

Personalised recommendations